Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Biostime International Holdings Limited

合生元國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1112)

DELAY IN DESPATCH OF CIRCULAR

MAJOR AND CONNECTED TRANSACTION
ENTRY INTO OF THE ROLL-UP SHAREHOLDERS' AGREEMENT
FOR THE GRANT OF THE HOLDCO PUT OPTION
IN RESPECT OF THE ACQUISITION OF
APPROXIMATELY 17% EQUITY INTEREST
IN BIOSTIME AUSTRALIA HOLDINGS
FOLLOWING THE PROPOSED EXERCISE OF ROLL-UP CALL OPTION

Reference is made to the announcement of Biostime International Holdings Limited (the "Company") dated 19 July 2016 (the "Announcement"). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a Circular containing, among others, (i) details of the Transactions; (ii) basic information of the Target Group; (iii) a letter from the Independent Board Committee regarding the relevant aspects of the Transactions to the Independent Shareholders; (iv) the letter of advice from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders regarding the relevant aspects of the Transactions; and (v) notice of the EGM was expected to be dispatched to the Shareholders on or before 15 August 2016.

As additional time is required to finalise the contents of the Circular, the Company expects that the date of despatch of the Circular will be postponed to a date falling on or before 31 August 2016.

By order of the Board

Biostime International Holdings Limited

Luo Fei

Chairman

Hong Kong, 15 August 2016

As at the date of this announcement, the executive Directors of the Company are Mr. Luo Fei and Mr. Radek Sali; the non-executive Directors of the Company are Dr. Zhang Wenhui, Mr. Wu Xiong, Mr. Luo Yun and Mr. Chen Fufang; and the independent non-executive Directors of the Company are Dr. Ngai Wai Fung, Mr. Tan Wee Seng and Professor Xiao Baichun.